BOSTON, MA—March 15, 2011—Stonebridge Associates announced today that it served as exclusive financial advisor to Cambrooke Foods  in its recent Series A financing from Galen Partners. Cambrooke, a rapidly growing provider of high quality branded specialty medical foods, will use the proceeds to expand its line of complete dietary therapy products for patients with certain inborn errors of metabolism (IEM). The funds will also be used to build out the corporate infrastructure, accelerate plans for international expansion, and expand its product platform to address clinical nutrition applications for patients with other disorders.
Cambrooke has launched several new formula products over the past few years, the most recent of which, BetterMilk™, is based on a proprietary formulation of glycomacropeptide (GMP), licensed from the University of Wisconsin. BetterMilk™ represents the first intact protein used in dietary management of IEM disorders, and clinical studies have shown improved patient outcomes using GMP-based products over traditional therapeutic options.
Working with Cambooke's founders, Stonebridge developed a financing strategy, prepared offering materials, identified suitable financing sources, and managed the due diligence process. Cambrooke's co-founder and CEO, David Paolella, says "Stonebridge provided exceptional guidance throughout the entire process. They conducted extensive analysis and in-depth research to identify an investor who not only understood our specialized market, but could also add value to our business. I am extremely pleased with the outcome, as it will allow us to realize our goal to help more families like ours who require specialized dietary therapies."
|
Stonebridge Associates specializes in providing merger and acquisition (M&A), divestiture, private placement, and strategic financial advisory services to middle market and emerging growth technology companies. Applying industry experience and structuring expertise to every engagement, Stonebridge Associates develops creative solutions to help clients achieve superior outcomes. Since 1986, Stonebridge has closed over $3 billion in private financings and advised on over 300 M&A transactions and advisory assignments. Member FINRA/SIPC.
Cambrooke Foods manufactures innovative clinical nutrition products for patients who require specialized "diet for life" therapies. Founded in 2000 by the parents of two children with classical PKU, Cambrooke Foods' first mission is to serve the community of those requiring dietary therapy. The company is currently focused on providing a line of GMP-based products for people diagnosed with IEM. The first product in this line, BetterMilk GMP, has been extremely well received in the marketplace.
Galen Partners is a leading healthcare private equity firm that focuses on growth equity investments in healthcare technology-enabled services, medical devices and specialty pharmaceutical companies. Galen has invested in more than 70 companies since 1990 and has nearly $1 billion in assets under management. The firm leads investments of $10 million to $30 million of private equity capital. Galen continues its tradition of strategic collaboration and active partnership with its portfolio company management teams to build healthcare market leaders.
|
Connecting to Facebook